Risky Move

February 24, 2017

When transporting temperature-sensitive regenerative therapies, companies can mitigate risk by employing a Supply Chain Quality by Design (SC-QbD) process during clinical and commercial distribution. By leveraging innovative shipping technologies, including continuous monitoring, the industry can achieve better visibility into the dynamic handling and condition of the biologic material and its packaging throughout its journey. In a recent article in International Clinical Trials, Mark W. Sawicki, Ph.D., chief commercial officer of Cryoport, discusses how real-time data provides significant analytical tools for actionable Design of Experiment and QbD methodologies that will ultimately protect the quality of the material transported and the resultant data. Read more >

Tags: Global Cold Chain Logistics, Temperature Controlled Logistics, Frozen Biological Shipping